Adam Lazorchak Email and Phone Number

Be Bio’s mission is to develop innovative, best-in-class, precision gene engineered B cell medicines.As Be Bio’s 15th employee, I founded Be Bio’s non-clinical in vivo Pharmacology and Translational Sciences programs, building high performing Teams of over 10 scientists (Research Associate though Sr. Principal Scientist). I currently lead the in vivo pharmacology program, directing animal model development strategy (murine and non-human primate), overseeing in vivo study design & execution, and contributing to regulatory strategy and filings. Key achievements include:Developing in the vivo pharmacology strategy and directing IND enabling non-clinical in vivo pharmacology studies that led to the successful IND clearance of BE-101 in 2024, a first-in-class gene edited B cell therapy for the treatment of Hemophilia B.Establishing Be Bio’s non-human primate (NHP) research program in collaboration with Cynthia Dunbar M.D. (NHLBI/NIH) to successfully demonstrate two foundational attributes of the B cell medicine platform: cellular engraftment without preconditioning and engraftment upon re-dose.Successfully developing novel in vivo models to support Be Bio’s preclinical pipeline and methods for precision gene engineering of non-human primate B cells.

Non-clinical in vivo pharmacology group leader (5 direct reports) supporting the translational development of bintrafusp alfa (M7824), a clinical stage, fist-in-class, bi-functional anti-PD-L1/TGF-beta trap for the treatment of cancer.Advanced bintrafusp alfa translational research by identifying novel clinical combination therapies and defining drug mechanism of action; resulting in 3 patents and 3 peer-reviewed publications

Non-clinical pharmacology (in vitro and in vivo) and biomarker discovery Team leader (2 direct reports) supporting Curis's first-in-class oral, small molecule immune checkpoint antagonist drug programs. Led Investigational New Drug (IND) enabling pharmacology studies supporting the development of CA-170, a small molecule antagonist of the PD-L1 and VISTA immune checkpoint pathways.Directly contributed to the pharmacology and first-in-human starting dose rationale leading to the successful IND clearance of CA-170.

Led the preclinical development of ImStem’s human embryonic stem cell derived mesenchymal stromal cell (hESC-MSC) immunotherapy for the treatment of multiple sclerosis. Identified mechanisms through which hESC-MSCs mediate T cell immunosuppression and identified biomarkers associated with hESC-MSC mediated T cell therapeutic activity, resulting in 2 peer reviewed publications.Conducted preclinical proof-of-concept studies showing that hESC-MSCs inhibit pathogenic inflammatory T cell immune responses in mouse models of multiple sclerosis and inflammatory bowel disease.Identified IL-6 as a biomarker associated with hESC-MSC therapeutic activity and published these findings in Stem Cell Reports.

My research explored how the intracellular signaling pathways controlling cell growth and metabolism influence the immune system's ability to fight infection and the development of blood cancer. My research let to 7 peer-reviewed publications and the following key discoveries:The development of a novel method to treat blood cancer based on the synergistic activity of Sirolimus and Tanespimycin. This work was published in the journal Blood.The discovery that mTOR signaling prevents DNA damage in developing B lymphocytes and regulates B cell development. This work was published in the journal Molecular Cell and was successfully awarded competitive funding from the Leukemia & Lymphoma Society and US Department of Defense.